DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01507311

CompletedPhase 1

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Effect of NNC90-1170 on Pulsatile Insulin Secretion in Type 2 Diabetic Patients. A Double-blind, Placebo-controlled, Randomised, Single-dose, Cross-over Trial

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

11

actual

Study population

Type 2 diabetes

Key I/E criterion

•BMI 24-35

Primary endpoint

•Insulin secretory burst mass

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01507311
Org study IDNN2211-1219

Timeline

Milestones

Study first posted2012-01-10estimated
Last update posted2017-01-24estimated
Study start1999-09 (month precision)
Primary completion1999-12actual (month precision)
Study completion1999-12actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months
•BMI (Body Mass Index) between 24 and 35 kg/m^2 (both inclusive)
•Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
•Anti-GAD (glutamic acid decarboxylase) negative

Exclusion criteria

•Known or suspected allergy to trial product or related products
•Receipt of any investigational drug within three months prior to this trial
•Recurrent severe hypoglycaemia as judged by the investigator
•Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
•Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere
•with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
•Liver or renal disease

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Safety / tolerability / PK
1
Other clinical outcomes
1

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

Insulin secretory burst mass

descriptive

Secondary/protocol endpoint/low confidence

Insulin secretory pulse mass, amplitude, frequency and regularity

descriptive

Secondary/protocol endpoint/low confidence

Insulin secretion

descriptive, improvement

Secondary/protocol endpoint/low confidence

Glucagon response

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Gastric emptying rate

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.